Share this article

Edwards Lifesciences has signed a definitive agreement to acquire medical technology company CAS Medical Systems (CASMED) in an all-cash transaction valued at around $100m, or $2.45 per share.

CASMED focuses on the non-invasive monitoring of tissue oxygenation in the brain.

It provides hospitals, emergency medical services and original equipment manufacturers (OEMs) with FORE-SIGHT Cerebral Oximeters to detect tissue hypoxia.

“Subject to customary closing conditions, the acquisition is set to be completed in the second quarter of this year.”

The oximetry products are said to accurately and non-invasively measure tissue oxygenation in the brain.

Edwards Lifesciences expects the FORE-SIGHT technology to complement its HemoSphere hemodynamic monitoring platform.

Edwards Lifesciences critical care corporate vice-president Katie Szyman said: “Cerebral oximetry technology provides an important indicator of oxygen levels in the brain, which can enhance clinician decision-making.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

“We believe the incorporation of CASMED’s FORE-SIGHT technology into Edwards’ leading hemodynamic monitoring platform, along with Edwards’ predictive analytics capability, will strengthen Edwards’ leadership in smart monitoring technologies by providing physicians with a more comprehensive status of their surgical and critically ill patients.”

The company, in alliance with CASMED, developed a smart cable and software module that facilitates the connection between the FORE-SIGHT sensor and the HemoSphere monitoring platform.

While this technology has obtained the European CE-Mark, it is yet to receive 510(k) clearance from the US Food and Drug Administration (FDA).

CASMED president and CEO Thomas Patton said: “We are pleased with this opportunity to bring together CASME’s expertise in brain and tissue oxygenation monitoring with Edwards’ long history of leadership in hemodynamic monitoring.

“We are confident that the combination of these technologies will result in an important measurement tool for physicians that can empower them to improve care.”

Subject to customary closing conditions, the acquisition is set to be completed in the second quarter of this year.